Phase II study of carboplatin and weekly paclitaxel combination chemotherapy in advanced non-small cell lung cancer: a Kansai Clinical Oncology Group study.

The objective of this phase II study was to evaluate the efficacy and toxicity of carboplatin and weekly paclitaxel combination chemotherapy in previously untreated, advanced non-small cell lung cancer (NSCLC). Patients received paclitaxel at a dose of 70 mg/m(2) on days 1, 8, 15, and carboplatin with the target dose of area under the curve (AUC) of 6 on day 1 every 28 days. Forty-six patients were enrolled. A median of four cycles (range, 1-13) were administered. Complete response was observed in one patient (2.2%) and partial response in 23 patients (50%), yielding an overall intent-to-treat response rate of 52.2% (95% confidence interval, 37.8-66.6%). The median survival time was 395 days and 1-year survival rate was 51.4%. Toxicities were mild. Twelve patients (26%) had grade 3 and three patients (7%) had grade 4 neutropenia. Grade 3 thrombocytopenia was seen in four patients (8%). Massive hematoemesis due to duodenal ulcer was observed in one patient, but no other patients experienced grade 3 or more non-hematological toxicities. There was no treatment-related death. Carboplatin and weekly paclitaxel combination chemotherapy is an efficacious and feasible regimen in patients with advanced NSCLC, and this treatment will be a reasonable alternative to the conventional triweekly regimen of paclitaxel and carboplatin.

Regeneration of serous membrane on gelatin-processed polyglycolic acid (PGA)-human collagen membrane and its efficacy on the prevention of adhesion.

We prepared a complex membrane consisting of human amnion-derived collagen membrane and polyglycolic acid (PGA), and then gelatin was crosslinked using heat on one side of the complex membrane to prepare a membrane that can prevent adhesion (gelatin-processed PGA-human collagen membrane). Applying this membrane to a rabbit cecum-abdominal-wall-adhesion model, the prevention of adhesion and tissue regeneration were investigated. The animals were sacrificed 2 and 12 weeks after surgery and then examined. The adhesion scores in the short-term observation group (2 weeks after surgery) and long-term observation group (12 weeks after surgery) were 1.0 +/- 2.4 and 0.8 +/- 2.0, respectively, showing a significant prevention of adhesion compared to the control value of 6.3 +/- 2.5 (p < 0.01). Histologically, gelatin was not absorbed, and outgrowth of connective tissue accompanied by capillary blood vessels was observed between the sample and the cecum in the short-term observation group. In the long-term observation group, the sample was completely absorbed, and serous membrane was regenerated on the surface of connective tissue. Based on these findings, it is possible to use gelatin-processed PGA-human collagen membrane as a filling material with both an adhesion-preventing effect and tissue-regenerating function.